Compare NBRG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBRG | SPRO |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 71.0M |
| IPO Year | 2025 | 2017 |
| Metric | NBRG | SPRO |
|---|---|---|
| Price | $10.09 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3K | ★ 364.7K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $9.59 | $1.08 |
| 52 Week High | $10.09 | $3.08 |
| Indicator | NBRG | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 71.53 | 33.05 |
| Support Level | $9.96 | $1.13 |
| Resistance Level | N/A | $1.29 |
| Average True Range (ATR) | 0.01 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 100.00 | 14.29 |
Newbridge Acquisition Ltd is a blank check company.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.